ReviewJournal of molecular and cellular cardiology2024
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.
Review in Journal of molecular and cellular cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Impact of CaInternational journal of molecular sciences · 2026Review
- Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery.Journal of clinical medicine · 2026Review
- Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation.Cardio-oncology (London, England) · 2026Article
- Risk factors for atrial fibrillation after lung cancer surgery: a meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Cancer Is a Major Determinant of Postoperative Atrial Fibrillation After Cardiac Surgery.Journal of clinical medicine · 2025Article
- Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.Cardio-oncology (London, England) · 2024Review
- Review
- Cancer, Inflammation, and Thrombosis: Drivers of Atrial Fibrillation in Oncology Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Atrial fibrillation (AF) is a common arrhythmic complication in cancer patients and can be exacerbated by traditional cytotoxic and targeted anticancer therapies. Increased incidence of AF in cancer patients is independent of confounding factors, including preexisting myocardial arrhythmogenic substrates, type of cancer, or cancer stage. Mechanistically, AF is characterized by fast unsynchronized atrial contractions with rapid ventricular response, which impairs ventricular filling and results in various symptoms such as fatigue, chest pain, and shortness of breath. Due to increased blood stasis, a consequence of both cancer and AF, concern for stroke increases in this patient population. To compound matters, cardiotoxic anticancer therapies themselves promote AF; thereby exacerbating AF morbidity and mortality in cancer patients. In this review, we examine the relationship between AF, cancer, and cardiotoxic anticancer therapies with a focus on the shared molecular and electrophysiological mechanisms linking these disease processes. We also explore the potential role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in the management of anticancer-therapy-induced AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.